AngioJet experience from the multi-center STENT Registry.
To explore the utilization and clinical outcomes of AngioJet Rheolytic thrombectomy from the Strategic Transcatheter Evaluation of New Therapies (STENT) multi-center prospective registry from May 2003 through December 2005. Prospective consent was sought for all consecutive percutaneous coronary intervention (PCI) patients at all institutions and achieved in 84% of all patients. Of these, clinical follow-up at 9 months was achieved in 94% of eligible patients at all institutions. Of a total of 9,707 patients, AngioJet was utilized in 3-4% of all procedures, including 12-14% of all procedures with thrombolysis in myocardial infarction (TIMI) grade 3 thrombus or greater and 10-12% of acute evolving MI patients. Nine-month clinical outcomes showed similar mortality rates for patients treated with AngioJet (5.0%) versus those with no thrombectomy (6.5%) for patients with thrombus grade 3 or greater, despite the higher clinical risk profile of the AngioJet patient population due to a higher percentage of cardiogenic shock and larger thrombus. The results of this larger, multi-center registry indicate that AngioJet thrombectomy, when selected in general clinical practice for high risk patients with thrombus, results in non-significant numerically lower rate of mortality with no indication of safety issues.